STAT+: In Minnesota, researchers explore how to audit health AI models on a patient level
As hospitals and companies continue to leverage artificial intelligence in medicine, researchers are also grappling…
Author: STAT
Opinion: Drug developers navigating ‘biology’s century’ need a model. We made one
STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry…
STAT+: Democratic lawmakers press pharmacy chains on abortion pill access
More than a dozen Democratic lawmakers are urging some of the nation’s largest drugstore chains…
STAT+: PhRMA chief dings health insurers over drug prices at their own conference
WASHINGTON — The head of the brand drug lobby used an in-person health insurance industry…
A letter from the executive editor: The 2023 STATUS List
After months of vigorous deliberations, I’m thrilled to announce our 2023 STATUS List — the…
National Academies calls for transforming use of racial and ethnic labels in genetics research
Saying genetics researchers inconsistently and inappropriately use racial and ethnic labels that fail to capture…
STAT+: Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA
Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question:…
EPA announces proposed drinking water limits for six ‘forever chemicals’
The Environmental Protection Agency for the first time on Tuesday proposed enforceable regulations for “forever…
STAT+: Pharmalittle: Novo to cut some insulin prices by up to 75%; Veterans Administration to cover new Alzheimer’s treatment
Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, in…
STAT+: Novo Nordisk to lower insulin prices by up to 75% amid growing pressure
Under mounting pressure, Novo Nordisk plans to cut U.S. list prices for several insulin products…
‘Leave the chocolate milk out of this’: School cooks, parents, kids push back on USDA effort to make lunches healthier
WASHINGTON — The feds are coming for your kids’ chocolate milk. At least, so says…
STAT+: Setting aside the thorniest issues around CRISPR babies, scientists say embryo-editing research should proceed
LONDON — The Francis Crick Institute is a glimmering chameleon of a building, spanning four…
Opinion: NRC: be straight about when clinicians need to report errors that lead to radiation exposure
A recent action by the U.S. Nuclear Regulatory Commission (NRC) should have protected patients who…
‘This is a nonpartisan issue’: Planned Parenthood’s Alexis McGill Johnson on fighting for reproductive rights
In the wake of the Supreme Court’s decision to overturn Roe v. Wade, the news…
STAT+: Veterans Health Administration will cover the newest Alzheimer’s drug
In an unexpected move, the Veterans Health Administration announced Monday that it will widely cover…
STAT+: Illumina has been ignoring its investors, but it can’t ignore Carl Icahn
Illumina, the DNA sequencing giant whose stock has fallen 40% in two years, already had…
.jpg)
STAT+: 102 hours of chaos: How SVB’s collapse rattled the biotech industry
Paul Rennert was surprisingly energized after deplaning a transatlantic flight in Boston Thursday evening. He…
STAT+: Pharmalittle: Biogen exec who quarterbacked Aduhelm leaves; Pfizer to buy Seagen for $43 billion
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion
Sanofi said Monday that it is acquiring Provention Bio, makers of a diabetes treatment, for…
STAT+: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion
Pfizer said Monday it is acquiring Seagen, a maker of targeted cancer drugs, for $43…
Opinion: The second age of psychedelic therapies for mental health
Psychedelics like psilocybin and ketamine are being touted as the next generation of treatment for…
STAT+: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
When NaviHealth began building a business around using algorithms to scrutinize the care of older…
Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
An algorithm, not a doctor, predicted a rapid recovery for Frances Walter, an 85-year-old Wisconsin…
STAT+: Biogen’s Samantha Budd Haeberlein, an architect of Aduhelm, leaves company
Samantha Budd Haeberlein, the Biogen senior executive who supervised the development and controversial approval of…
Prostate cancer treatment can wait for most men, study finds
Researchers have found long-term evidence that actively monitoring localized prostate cancer is a safe alternative…
STAT+: FDA approves first treatment for Rett syndrome, a genetic neurological disease
The Food and Drug Administration on Friday approved the first treatment for Rett syndrome, a…
Covering new weight loss drugs could strain Medicare, policy experts warn
The emergence of highly effective obesity drugs has spurred renewed efforts to get Medicare to…
STAT+: SVB, biotech’s bank of choice, just failed. It could have ripple effects
Silicon Valley Bank, which does business with roughly half of the nation’s tech and biotech…
STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap
And so, another working week will soon draw to a close. Not a moment too…
Opinion: Ranked to fail: Does gatekeeping affect diversity in The Match?
For graduating medical students hoping to secure a residency training position — and that’s virtually…
Opinion: Clearing the patent thicket: A pathway to faster generic drug approvals
Revelations that AbbVie, the manufacturer of Humira, made more than $100 billion in extra profits…
STAT+: Several years later, AstraZeneca says its drug extends life for some early-stage lung cancers
Ever since the Food and Drug Administration approved osimertinib for some early-stage lung cancer patients…
STAT+: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices
By law, Medicare will have to take a medication’s efficacy and its research and development…
STAT+: Biden makes big demands for cancer research and new ARPA-H agency
President Biden is banking on longtime bipartisan interest in eliminating cancer deaths to secure some…
Biden administration requests $20 billion cash infusion to bolster public health
WASHINGTON — The Biden administration is calling for a big boost for public health funding…
Listen: Robert Califf on how drugs get approved, plus the nascent revolution in obesity
What keeps the FDA commissioner up at night? How will Ozempic change the world? And…
STAT+: Biden makes drug pricing a central part of his deficit reduction plans
WASHINGTON – President Biden made lowering drug prices a key part of his budget with…
STAT+: Insulin for $20 a vial? Sanders pushes bill for price caps on the diabetes treatment
Now that Eli Lilly is cutting prices on some of its insulin products, U.S. Sen….
With a $11 billion price tag, the White House pitches a plan to end hepatitis C
WASHINGTON – The Biden administration is calling on Congress to fund a more than $11…
U.S. requires new info on breast density with all mammograms
WASHINGTON — All U.S. women getting mammograms will soon receive information about their breast density,…
STAT+: Mice with two fathers and base-edited baby monkeys highlight potential — and limitations — of hereditable gene editing
LONDON — Scientists at this year’s genome editing summit spent Tuesday showing the world just…
STAT+: Pharmalittle: Pharmacies are battlegrounds in the abortion debate; Lilly Alzheimer’s drug failed to prevent memory loss in study
Rise and shine, folks, another busy day is on the way. Already, there was a…
STAT+: An unlikely new 340B alliance emerges between PhRMA and community health centers
WASHINGTON — An unusual new alliance of the brand-drug lobby PhRMA and community health centers…
Opinion: Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails
A decade ago, I had pegged gene and cell therapies as the next frontier. As…
STAT+: ‘Emotional hunger’ vs. ‘hungry gut’: The attempt to subtype obesity and tailor treatments
This is part of a series about new obesity drugs that are transforming patients’ lives,…
Watch: The troubled history of BMI, the body mass index
The body mass index, or BMI, is the formula that’s used most often to diagnose…
Pfizer CEO Albert Bourla maxed out campaign contributions to Dr. Oz ahead of midterm elections
WASHINGTON — Pfizer CEO Albert Bourla made the maximum possible campaign contribution to Mehmet Oz…
‘Truth is losing the battle’: FDA commissioner on grappling with a wave of health misinformation
The Food and Drug Administration is considering whether it needs to revamp guidance on how…
STAT+: Medicare chief on the new drug price negotiation program’s operations, hiring, and timelines
WASHINGTON — Medicare officials are still hammering out the technical specifics of how the massive…
Revamped Covid panel argues for research limits, even bans
WASHINGTON — Pathogen-altering research is back under fire here, as Republican lawmakers argue it should…